48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf192 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Elisa de Lazzari und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain. Hauptthemen laut MEDLINE: Lamivudine, Heterocyclic Compounds, 3-Ring, HIV Infections, Body Composition. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Red de Investigación en Sida, ViiV Healthcare.
Abstract (Originalsprache)
Background
Switching to dolutegravir plus lamivudine has been associated with weight gain. We aimed to assess factors associated with weight gain and changes in body composition in people with HIV switching to dolutegravir plus lamivudine in the DOLAM trial (EudraCT 201500027435).
Methods
People with HIV on suppressive triple therapy were randomized to switch to dolutegravir plus lamivudine or to continue triple therapy. Weight and height were measured, and dual X-ray absorptiometry (DXA) scans were performed at baseline and 48 weeks. Factors associated with 48 week weight change were estimated using linear regression models adjusted for weight at baseline. DXA-derived changes were assessed using age- and sex-adjusted linear or log-linear mixed-effects regression models.
Results
One hundred and eighty (68% of the DOLAM trial participants) (dolutegravir plus lamivudine, n = 88; triple therapy, n = 92) participants contributed with paired baseline and 48 week DXA scans. Mean (95% CI) weight changes were 1. 362 kg (0.437–2.287) in the dolutegravir plus lamivudine arm and 0.199 kg (−0.742 to 1.140) in the triple therapy arm. Treatment with dolutegravir plus lamivudine and age were independently associated with greater weight change at 48 weeks. DXA-derived changes in body fat mass (<0.5% in both arms), lean mass (<7% in both arms) and bone mineral density scans (<0.5% in both arms) did not differ between arms.
Conclusions
Although weight at 48 weeks increased with dolutegravir plus lamivudine but not with triple therapy in the DOLAM study, we did not detect any significant DXA-derived changes in body fat, lean mass or bone mineral density between arms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Hospital Clínic-IDIBAPS, Barcelona, Spain.
- Department of Medicine, University of Barcelona, Barcelona, Spain.
- Department of Endocrinology and Metabolic Diseases, Creu Blanca, Barcelona, Spain.
- Department of Infectious Diseases, Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Spain.
- Department of Infectious Diseases, Hospital Vall d'Hebron, Barcelona, Spain.
- Department of Internal Medicine, Hospital de Sant Pau, Barcelona, Spain.
ORCID-Profile: Elisa de Lazzari, Pere Domingo, Juan Tiraboschi, Ana Gonzalez-Cordon, Berta Torres, Esteban Martinez
Förderung
- Instituto de Salud Carlos III
- Red de Investigación en Sida
- ViiV Healthcare
- CIBERINFEC-Consorcio Centro de Investigación Biomédica en Red
- Ministerio de Ciencia e Innovación and Unión Europea-NextGenerationEU
- Hospital Clínic, Barcelona
- CIBERINFEC—Consorcio Centro de Investigación Biomédica en Red
- Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU
Zitieren
APA
de Lazzari, E., Di Gregorio, S., Rojas, J., Curran, A., Domingo, P., Negredo, E., Tiraboschi, J., Gonzalez-Cordon, A., Torres, B., Sempere, A., Inciarte, A., Gatell, J. M., Blanco, J. L., Martinez, E., & DOLAM study group (2025). 48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf192
Vancouver
de Lazzari E, Di Gregorio S, Rojas J, Curran A, Domingo P, Negredo E, et al. 48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf192
BibTeX
@article{deLazzari2025,
author = {de Lazzari, Elisa and Di Gregorio, Silvana and Rojas, Jhon and Curran, Adria and Domingo, Pere and Negredo, Eugenia and Tiraboschi, Juan and Gonzalez-Cordon, Ana and Torres, Berta and Sempere, Abiu and Inciarte, Alexy and Gatell, Josep M and Blanco, Jose L and Martinez, Esteban and DOLAM study group, DOLAM study group},
title = {48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf192}
}
EUVIMED